An estimated 21.0 million U.S. adults (8.3%) experienced at least one major depressive episode. Prevalence rates vary significantly by demographics: 13.9% for multiracial adults, compared to 8.9% for ...

Major depressive disorder (MDD) is a disturbance of mood that may have persistent and long-term consequences impacting patients’ overall level of functioning and quality of life. 1 Historically, ...

Depression, one of the most prevalent mental health disorders worldwide, is characterized by persistent feelings of sadness, ...

Overwhelming feelings of despair and hopelessness are increasingly very common among individuals of several age groups. About 21 million people (i.e. 8.3 percent of adults nationwide), in fact, have ...

Credit: Otsuka. At this time, the product is available to patients for a discounted price of $50; the full price is $200. Rejoyn ™, the first prescription digital therapeutic cleared for the treatment ...

The approval of medicines called second-generation antipsychotics has allowed major depressive disorder (MDD) and other conditions linked to it to be treated. A person with MDD is usually prescribed ...

Johnson & Johnson today announced a new analysis of Phase 3 data which found CAPLYTA® (lumateperone), in combination with an antidepressant, showed significantly greater remission rates in adults with ...

Researchers from Hiroshima University in Japan and collaborating institutions have found that adults with asthma who ...

Mood symptoms alone do not account for the extent of disability associated with MDD. 12 Cognitive impairment, 1 of the 9 core symptoms of MDD (see Table 1), is significantly associated with impaired ...